Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/40450
標題: Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer
作者: Huang, K.H.
邱繡河
Chiou, S.H.
Chow, K.C.
Lin, T.Y.
Chang, H.W.
Chiang, I.P.
Lee, M.C.
周寬基
關鍵字: aldo-keto reductase family 1-member C2
disease progression
drug
resistance
prostatic cancer
cell lung-cancer
hepatocyte growth-factor
dihydrodiol dehydrogenase
cigarette-smoking
risk-factor
expression
resistance
induction
carcinoma
akr1c2
期刊/報告no:: Histopathology, Volume 57, Issue 3, Page(s) 384-394.
摘要: Aims: Prostatic cancer is resistant to chemotherapy. Expression of aldo-keto reductase 1C (AKR1C) has been associated with drug resistance and disease progression in several cancers. The aim was to investigate the relationship between AKR1C expression and disease progression in prostatic cancer. Methods and results: From January 1996 to December 2005, 86 pathological samples were collected from patients with prostatic cancer. A tissue microarray containing 31 prostatic cancers from American patients was used for comparison between Chinese and American patients. Using immunohistochemistry, aldo-keto reductase family 1, member C2 (AKR1C2) expression was assessed in tissue sections. The AKR1C2 was determined by two-dimensional immunoblotting and DNA sequencing of reverse transcriptase-polymerase chain reaction products. The relationship between AKR1C2 expression and clinicopathological variables was statistically analysed. In vitro, the association between AKR1C2 expression and drug resistance was investigated in androgen-sensitive and androgen-insensitive prostatic cancer cells. DNA sequencing and two-dimensional immunoblotting showed that prostatic cancer expressed AKR1C2. It was overexpressed in 77 of 86 (89.5%) Chinese and in 28 of 31 (90.3%) American samples. No difference was found in AKR1C2 expression between Chinese and American prostatic cancer patients. In vitro, increased expression of AKR1C2 and prostaglandin F2 alpha correlated with cytoprotection against anticancer drugs and lycopene. Conclusion: Overexpression of AKR1C2 is associated with disease progression in prostatic cancer.
URI: http://hdl.handle.net/11455/40450
ISSN: 0309-0167
文章連結: http://dx.doi.org/10.1111/j.1365-2559.2010.03647.x
Appears in Collections:生物醫學研究所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.